AstraZeneca announces discovery of a new class of antibiotic

Article Abstract:

AstraZeneca has announced the discovery of a new class of antibiotic agents with the potential to combat the escalating problem of drug-resistant bacteria. The compound belongs to an entirely novel structural class and lacks cross-resistance with current classes, thereby giving it a clear future role as resistance to current antibacterials continues to rise.

Antibiotics

---

'Fast-track' drug approvals hit speed bumps in Japan

Article Abstract:

Iressa (gefitinib) a cancer drug is the fastest approved non-AIDS-related-drug by Japan. Families of patients who died after consuming Iressa filed a lawsuit against manufacturer AstraZeneca and the Japanese government.

United Kingdom, Japan, Legal issues & crime, Government regulation (cont), Government regulation, Legal/Government Regulation, Laws, regulations and rules, Drug approval

---

Survey hints at uneven adoption of cancer vaccine

Article Abstract:

A survey that indicates an uneven adoption of the cancer vaccine Gardasil by people of different age-groups from different communities is discussed.

United States, Commodity & service prices, Prices and rates, Surveys, Company pricing policy, Merck & Company Inc., Cancer vaccines, Survey

Similar abstracts:

• Abstracts: Intraobserver and interobserver variability of the amniotic fluid index. Intraobserver and interobserver variability for the histologic diagnosis of chorioamnionitis
• Abstracts: Aberrant crypt foci of the colon as precursors of adenoma and cancer. Taming transplantation with T cells
• Abstracts: Aneurysm treatments expand. Cocaine addiction therapy -- are we partially there? Cocaine's long run
• Abstracts: The interval between pregnancies and the outcome of subsequent births. Small-for-gestational-age infants and risk of fetal death in subsequent pregnancies
• Abstracts: Unstable angina pectoris. Time to treatment in primary percutaneous coronary intervention

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.